



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/451,739	11/30/1999	DIRK JAGER	LUD-5615	9448

24972 7590 05/14/2003
FULBRIGHT & JAWORSKI, LLP
666 FIFTH AVE
NEW YORK, NY 10103-3198

EXAMINER

NICKOL, GARY B

ART UNIT	PAPER NUMBER
----------	--------------

1642

DATE MAILED: 05/14/2003

24

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

09/451,739

Applicant(s)

JAGER ET AL.

Examiner

Gary B. Nickol Ph.D.

Art Unit

1642

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 11 March 2003.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 80-97 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 80 and 85-97 is/are rejected.
- 7) ☒ Claim(s) 81-84 is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☒ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on _____ is: a) ☐ approved b) ☐ disapproved by the Examiner.
- If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
- a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☒ Information Disclosure Statement(s) (PTO-1449) Paper No(s) 6.
- 4) ☐ Interview Summary (PTO-413) Paper No(s). _____.
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other: _____.

DETAILED ACTION

The Election filed March 11, 2003 (Paper No. 23) in response to the Office Action of February 14, 2003 is acknowledged and has been entered.

Claims 1-79 were cancelled.

Claims 80-97 were added and are currently pending.

Applicant's election with traverse of Group XIII, claim 79 in Paper No 23 is acknowledged. The traversal is on the ground(s) that the subject matter of Claim 79 de facto incorporates the subject matter of Group I, drawn to isolated nucleic acids including SEQ ID Nos: 4, 8, or 15. This argument has been considered and is found persuasive.

Specification

The preliminary amendment filed March 2, 2000 (Paper No. 5) is objected to. The attempt to change "set out at" to --- included in--- was not entered because it appears the section referenced to in the specification (page 12, line 10) was incorrect.

Further, on page 12, line 11, after the word "acids" the specification has been amended to recite "This is set forth as SEQ ID NO:6".. as requested in Paper No. 5. However, a second preliminary amendment filed June 27, 2000 (Paper No. 7) also requested a similar change on page 12, line 11 which inserted the text, "See SEQ ID NO:6". Applicant is requested to cancel one of these recitations to avoid redundancy. All of the other amendments have been properly incorporated into the specification.

Art Unit: 1642

Further, the specification on page 11, is objected to. Specifically, the 21 nucleotide sequence for SEQ ID NO:11 appears to be incorrect because the last nucleotide is listed as "C", but the as filed sequence listing reveals that the last nucleotide of SEQ ID NO:11 is a "T". Clarification and corrections are requested.

Claim Objections

Claim 86 is objected to under 37 CFR 1.75 as being a substantial duplicate of claim 87. (This also makes claims 88 and 89, 90 and 91, etc.. duplicates of each other). When two claims in an application are duplicates or else are so close in content that they both cover the same thing, despite a slight difference in wording, it is proper to object to the claims as being substantial duplicates. See MPEP § 706.03(k).

Claims 81-84 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 80, and 85-96 are indefinite for reciting the phrase "stringent conditions" in Claim 80. Stringent conditions are not defined by the claims, which include the full range of stringent conditions, that is from very permissive to very high stringency. Further, the specification does

Art Unit: 1642

not provide a standard for ascertaining the requisite degree of stringent conditions and one of ordinary skill in the art would not be reasonably apprised of the scope of the invention and would not be able to determine the metes and bounds of the claims.

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 80, and 85-96 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. The written description in this case only sets forth an isolated nucleic acid molecule comprising SEQ ID NO:4, 8, or 15 and or the “complete” complement thereof, and therefore the written description is not commensurate in scope with the claims drawn to naturally occurring polynucleotide sequences and or complementary sequences which hybridize under stringent conditions.

The claims are broadly drawn to an isolated nucleic acid molecule, the complementary sequence of which hybridizes, under stringent conditions, to one of the nucleotide sequences set forth in SEQ ID NO:4, 8, or 15.

Thus, the claims broadly include a whole universe of polynucleotide fragments. Clearly, it would be expected that a substantial number of the hybridizing or complementary polynucleotides encompassed by the claims **would not** share either structural or functional

Art Unit: 1642

properties with polynucleotides of SEQ ID NO:4, 8, or 15. Further, the claims do not require that the polynucleotides possess any particular biological activity, nor any particular conserved structure, or other disclosed distinguishing feature. Thus, the claims are drawn to a genus of polynucleotides defined only by sequence identity.

To provide adequate written description and evidence of possession of a claimed genus, the specification must provide sufficient distinguishing identifying characteristics of the genus. The factors to be considered include disclosure of complete or partial structure, physical and/or chemical properties, functional characteristics, structure/function correlation, methods of making the claimed product, or any combination thereof. In this case, the only factor present in the claim is a chemical structure in the form of a wide variety of potential hybridizing nucleic acids. Further, there is no identification of any particular portion of the structure that must be conserved. Accordingly, in the absence of sufficient recitation of distinguishing identifying characteristics, the specification does not provide adequate written description of the claimed genus.

Vas-Cath Inc. V. Mahurkar, 19 USPQ2d 1111, clearly states that “applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession *of the invention*. The invention is, for purposes of the ‘written description’ inquiry, *whatever is now claimed*.” (See page 1117). The specification does not “clearly allow persons of ordinary skill in the art to recognize that [he or she] invented what is claimed.” (See *Vas-Cath* at page 1116).

With the exception of SEQ ID NOs: 4, 8, or 15, the skilled artisan cannot envision the detailed structure of the encompassed polynucleotides and therefore conception is not achieved

Art Unit: 1642

until reduction to practice has occurred, regardless of the complexity or simplicity of the method of isolation. Adequate written description requires more than a mere statement that it is part of the invention and a reference to a potential method of isolating it. The nucleic acid itself is required. See *Fiers v. Revel*, 25 USPQ 2d 1601 at 1606 (CAFC 1993) and *Amgen Inc. V. Chugai Pharmaceutical Co. Lts.*, 18 USPQ2d 1016.

Therefore, only an isolated nucleic acid molecule comprising SEQ ID NO:4, 8, or 15 and or the complete complements thereof meets the written description provision of 35 U.S.C. §112, first paragraph. Applicant is reminded that *Vas-Cath* makes clear that the written description provision of 35 U.S.C. §112 is severable from its enablement provision (see page 1115).

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 80, 85-87, and 96 are rejected under 35 U.S.C. 102(b) as being anticipated by GARKAVSTEV *et al.* (WO 97/21809, June 19, 1997).

Garkavstev *et al.* teach an isolated nucleic acid molecule with 70% overall sequence similarity to SEQ ID NO:4 and 35% overall similarity to SEQ ID NO:8 (see attached sequence listings at the end of this Action) each of which would inherently hybridize under stringent conditions to SEQ ID NO:4. Garkavstev *et al.* further teach expression vectors operably linked to

Art Unit: 1642

a promoter comprising said nucleic acid molecule (page 19, lines 15-21), recombinant cells transformed or transfected with said isolated nucleic acids (page 5, lines 5+), and viral expression vectors (page 20, lines 20+) which would inherently be characterized as mutated or attenuated.

No claim is allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Gary B. Nickol Ph.D. whose telephone number is 703-305-7143.


The examiner can normally be reached on M-F, 8:30-5:00 P.M..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anthony Caputa can be reached on 703-308-3995. The fax phone numbers for the organization where this application or proceeding is assigned are 703-305-3014 for regular communications and 703-308-4242 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

Gary B. Nickol, Ph.D.
Examiner
Art Unit 1642

GBN
May 12, 2003



	Query Match	35.8%;	Score 276;	DB 184;	Length 1902;	
	Best Local Similarity	80.8%;	Pred. No. 2e-64;			
	Matches	422;	Conservative	0;	Mismatches	60;
					Indels	40;
					Gaps	7;
QY	2	AAGCGTTTCGGCGCGACGCCGACAACTAGAACCGGTGACCAACCGCGAC	61			
DB	343	AAGCGCTTCACGGCGCGACGCCGACAAACGAGAACCGGTGACCAACCGCGAC	401			
QY	62	CCACGACGACGCTCACTCTGGGACAGCCCAAGGAGAAAGAACCTCTTAAGAGAA	121			
DB	402	CCACGACGACGCGCGCTCTGGGACACCCCAAGGAGAAAGGCCAAGACCTCCAAAGAGAA	461			
QY	122	GCAGGGGCTTCATGGCGCAAGGCGTGAAGGCGGAGCGCTGCCCGGACACTCCCTCCATGCACCC	181			
DB	462	GAGCGGCTTCCAAAGGCCAAGGCGGAGCGAGCGAGGAGCTCCCTCCGCACTCCCTCCATGCACCC	521			
QY	182	CAGCGAGCC-----CTCTACTGGAGATGATTCGGCTGCAG	217			
DB	522	CAGCGAACCACGATACGTCTGTGTGCAAACCAAGGTCTCTTATGGGAGATGATTCGGCTGCAG	581			
QY	218	CA---ACGAAATGCCCATCGAGTGTTCGCTTCTCTGTGTGAGTCTCAACCATTAAC	274			

```

Db      582 CAACGACAGAGCCGCCATCGAGTGTCCATCTTCGTCGCGTGGGCTCAATCAATAAC 641
OY      275 AAGGCGAAGTGTACTGTCTCCAGATGCCGGGAGAAAGC-----ATGGCGAAAGC 326
Db      642 CAAGGCGAAGTGTACTGTCTCCAGATGCCGGGAGAAAGCAGAACACATGACAAAGC 701
OY      327 CCTTGAGAGTCCAGAAAAAAGAGGCGTTTAAACAGTACTTTGGGACATCGCTCTA 386
Db      702 CCGTAGAGAAATCCA--AAAAAGAGAGGCGTTTAAACAGTACTTTGGGACAGCGCCCTG 759
OY      387 ATAGTGGAGAGCAAAATTAAGCCAGTGTGATTAACATCCACCTTGGTGAAGTGC 446
Db      760 GT-GTGAGAGAGCAAAATAAACCC-GTGATTTATTATCAATGCTGCTTGTGAGGTGC 817
OY      447 AGGAAGTGTAAATGTATTTTAAAGAAATGTGTAGAG 488
Db      818 AAGGAGGTAAATGTATTTTAAAGAAATGTAGAAAG 859

```

RESULT 6

AAV62285 standard; cDNA; 1902 BP.

AAV62285;

18-JAN-1999 (first entry)

Partial INGI partial cDNA sequence.

ING1 gene; p33ING1; human; apoptosis; cell death; breast cancer;

brain tumour; gene therapy; tumour suppressor; ss.

Homo sapiens.

Key Location/Qualifiers

CDS 109..741

/tag- a

MO9844102-A2.

08-OCT-1998.

26-MAR-1998; 98MO-CA00277.

27-MAR-1997; 97US-0828158.

(UTR-) UNIT TECHNOLOGIES INT INC.

Garkavtsev I, Helbing CC, Johnston RM, Rabadoni K;

WPI; 1998-542700/46.

P-PSDB; AAW79674.

Modulating eukaryotic apoptosis by increasing p33ING1 activity -

using p33ING1 derivatives, to induce apoptosis in cancer cells, and

in the investigation of apoptotic pathways

Example 2; Fig 2; 66pp; English.

This is the nucleotide sequence of a human INGI (inhibitor of growth) partial cDNA clone that codes for a p33ING1 polypeptide (see AAW79674), a novel inhibitor of cell growth and a candidate tumour suppressor. INGI is a new gene that is expressed in normal mammary epithelial cells, but which is expressed only at lower levels in several cancerous mammary epithelial cell lines and is not expressed in many primary brain tumours. To isolate INGI, a subtractive hybridisation of breast cancer cell line cDNAs was performed with cDNA from normal mammary epithelial cells, and subtracted cDNAs were cloned into retrovirus vector pINX. Following passage through a packaging line, normal mouse mammary epithelial cells were infected, and infected cells were injected into mice. Putative transforming fragments from tumours were

Isolated by PCR (see AAV62290-91) and subcloned into INCX. An INGI fragment was obtained and used to screen normal human fibroblast and HeLa cell cDNA libraries. 2 clones were sequenced to obtain the partial INGI sequence. The complete cDNA sequence (see AAV62292) was obtained by RACE. A claimed method to potentiate apoptosis in a eukaryotic cell involves administering an active p33ING1 peptide or an oligonucleotide encoding such as a peptide. A claimed method for inhibiting apoptosis in a eukaryotic cell involves administering an antisense oligonucleotide. Also claimed are a method for determining the apoptotic characteristics of a eukaryotic cell, an assay for determining the level of p33ING1 activity in a eukaryotic cell, and an isolated eukaryotic cell substantially free of p33ING1 biological activity. The invention discloses INGI derivatives or variants that may be used to induce apoptosis in eukaryotic cancer cells.

Sequence 1902 BP; 574 A; 390 C; 462 G; 476 T; 0 other;

Query Match 35.8%; Score 276; DB 19; Length 1902;

Best Local Similarity 80.8%; Pred. No. 2e-64;

Matches 422; Conservative 0; Mismatches 60; Indels 40; Gaps 7;

```

OY      2 AAGCGTCTCGGCGGCGAGCGCAACACTGAAACGTGAGACCGCTCCAGCAACCGCAC 61
Db      343 AAGCGCTCAGCGGCGGCGAGCGCAACAGAACCGTGAGAACCGCTCCAGCAACCGCA- 401
OY      62 CCACGACGACGTCACTCGGCGGCGAGCGCCCAAGAGAGAAAGCCAGACCTTAAGAGAA 121
Db      402 CCACGACGACGCGGCGCTCGGCGACACCCAGAGAGAGAAAGCCAGACCTTAAGAGAA 461
OY      122 GCAGGCGCTCCATGAGCCCAAGGCGGAGCGGCGTCCCGCGAGACCTCCCATGACCC 181
Db      462 GAAGCGCTCCAGGCGCCAGAGCGGAGAGAGCGTCCCGCGAGACCTCCCATGACCC 521
OY      182 CACGAGCC-----CTCTACTGGAGATATCCGTGCGA 217
Db      522 CAACGAACCCAGTACTGTCTGTGCAACCAAGGTCTCTATGGGAGATATGCGTGCGA 581
OY      218 CA--ACGAATGCCCATGAGTGTCCGCTTCGTGTGAGTGTCAACCAATTAAC 274
Db      582 CAACGACGAGTCCCATGAGTGTCCCAAGTGTCCATCTGTGTGAGTGTCAATCATTAAC 641
OY      275 AAGCGCAAGTGTACTGTCTCAGATGCCGGGAGAAAGC-----ATGGCGAAAGC 326
Db      642 CAAGGCGAAGTGTACTGTCTCCAAAGTGTCCGCGGAGAAAGCAAGACCATGACAAAGC 701
OY      327 CCTTGAGAGTCCAGAAAAAAGAGGCTTAAACAGTACTTTGGGACATCGCTCTA 386
Db      702 CCGTAGAGAAATCCA--AAAAAGAGAGGCGTTTAAACAGTACTTTGGGACAGCGCCCTG 759
OY      387 ATAGTGGAGAGCAAAATTAAGCCAGTGTGATTAACATCCACCTTGGTGAAGTGC 446
Db      760 GT-GTGAGAGAGCAAAATAAACCC-GTGATTTATTATCAATGCTGCTTGTGAGGTGC 817
OY      447 AGGAAGTGTAAATGTATTTTAAAGAAATGTGTAGAG 488
Db      818 AAGGAGGTAAATGTATTTTAAAGAAATGTAGAAAG 859

```

RESULT 7

AAV69652 standard; cDNA; 2061 BP.

AAV69652;

27-AUG-1997 (first entry)

Tumour suppressor gene INGI full-length cDNA.

Tumour suppressor gene; INGI; p33ING1; breast cancer; brain cancer;

diagnosis; gene therapy; ss.

Homo sapiens.

RESULT 8
AAH28479
ID AAH28479 standard; DNA; 1143 BP.

Nucleotide sequence of a human cancer associated antigen.

Cancer associated antigen; INGI; tumour suppressor; cancer; vaccine; ss.

OS Homo sapiens.

FH	key	Location/Qualifiers
EE	CDG	15 000

```

/*tag= a
/xxxxx] count= "xxxx"

```

```

FT      /transl_except= "(pos: 124..136, aa: Pro, Ala)"
FT
FT      /product= "cancer associated antigen"
FT

```

PN W0200147959-A2.

PD 05-JUL-2001.

29-NOV-2000; 2000WO-US42334.

30-NOV-1999; 99US-0451739.
24-OCT-2000; 2000US-0503353

XX
PA (LMDW-) LMDWG INST CANCER F

PA (SLOK) SLOAN KETTERING INST CANCER RES.
PA (COBB) CORNETT, RES FOUND INC

PI Jager D, Stockert F, Scanlan M, Knuth

XX
DR
DR
DR

WPI; 2001-441706/47.
P-PSDB; AAB84697.

Example 4; Page 44; 62pp; English.

present sequence encodes a human cancer associated antigen. The sequence is the wildtype of the INGI gene, which is a tumour

CC suppressor gene candidate. The cancer associated antigen, polynucleotides
CC and polypeptides are useful for screening for the possible presence of
CC a pathological condition in a subject such as cancer. The cancer
CC associated antigen polypeptides are useful for producing vaccines.
XX
50 Sequence 1143 BP; 289 A; 291 C; 366 G; 197 T; 0 other;

Query Match	70.7%	Score 605.6	DB 22	Length 1143
Best Local Similarity	95.6%	Pred. No. 3.7e-109		
Matches 623; Conservative	0	Mismatches 29;	Indels 0;	Gaps 0

QY	206	CTAGGCTCTCTGGAGATGGTGTGTCCGGCCGGAGATGGAGATCCGAAAGAGACTTGGACAG	26
Db	160	CTGACCCGAGGGTGGGGGCGCGCTGGCCGTGGAAACGATCTCGAAAGGAGCTGAGACG	219
QY	266	TGCTACGAGCGCTTCAGTCCGCGAGACACAGACGGGCGCGCAAGACCGCGAGATGCTCACTGT	32
Db	220	TGCTACGAGCGCTTCAGTCCGCGAGACACAGACGGGCGCGCAAGACCGCGAGATGCTCACTGT	219
QY	326	GTGCAAGCGCGCGCTGATCCGCGACGACGAGAGCTGGGCGACGAGAAATCCAGATGCTGAGC	385
Db	280	GTGCAAGCGCGCGCTGATCCGCGACGACGAGAGCTGGGCGACGAGAAATCCAGATGCTGAGC	333

[illegible]

Db
400 GAGCGGACGACGGAGCTGTGGGGAGAACACTGTGGGCACACGCCGAAGTGGTCGCGCAGACAGG 459

07 566 CGCAACACGAGAACCCGTGAGAACCGCTCCAGCACCACGACGACGAGAGGGGCGCTCG 675

[illegible]

Db 580 GGCACACCCAGGAGGAAAGAGCCCAAGCTCCCAAGGAAGAAAGCCCTCCAAAGGCCAAG 6399

QY 686 GCGAGAGGAGAGGCGCTCCCTGCGAGACTCCCATGACCCCAAGCAAGCAACGACTACTGT 745

D6 640 GCGGAGGAGAGGCGCTCCCTGCCGACTCCCATCGACCCCAACGACCAAGTACTGT 659

Db	700	CTGTGCACCAACGAGCTCTCTTAATGGGGAATATGATGGCTGCACCAACGACGAGTGGCCCATC	759
Qy	806	GAGTGGTTCACATCTCTGTCGTCGTGGGGCTCAATCATTAACCCAAAGGCAAGT	857
Db	760	GAGTGGTTCACATCTCTGTCGTCGTGGGGCTCAATCATTAACCCAAAGGCAAGT	811

RESULT 9
AA69651
ID AA69651 standard; cDNA; 1902 BP.

XX	
AC	AAT69651;
XX	
DT	27-AUG-1997 . (first entry)
XX	

DE	Tumour suppressor gene ING1 partial cDNA.
XX	
KM	Tumour suppressor gene; ING1; p33ING1; breast cancer; brain cancer
KM	diagnosis; gene therapy; ss.
XX	
SS	<i>Homo sapiens</i> .

XX	Key	Location/Qualifiers
FH	CDS	109..741
FT		

```

FT      XX      /*tag= a
PN      XX      WO9721809-A1.
XX      XX      19-JUN-1997.
PD      XX
PF      XX      06-DEC-1996; 96WO-CA00819.
XX      XX
PR      XX      15-NOV-1996; 96US-0751230.
PR      XX      08-DEC-1995; 95US-0569721.
XX      XX
PA      XX      (U)NIV TECHNOLOGIES INT. INC.
XX      XX
PI      XX      Garkavstev I, Riabowol K;
DR      XX      WPI: 1997-332781/30.
DR      XX      P-PSDB; AAMI19118.
XX      XX
XX      XX      Isolated tumour suppressor gene, INGI - useful to develop products
PT      XX      for inhibiting or increasing cell proliferation, in particular for
PT      XX      treatment or diagnosis of cancer
XX      XX
XX      XX      Claim 1, Fig 2; 63pp; English.
XX      XX

```

CC A partial cDNA clone (AAT66651), designated ING1, codes for a novel
CC tumour suppressor protein p33ING1 (AAW19118) that is a potent
CC inhibitor of cell growth. It was isolated by subtractive
CC hybridisation between normal mammary and transformed epithelial
CC cDNAs, isolation of an antisense ING1 cDNA insert that caused
CC increased cell proliferation, and use of the insert to screen
CC normal human fibroblast and HeLa cDNA libraries. A complete ING1
CC sequence (AAT66652) was obtd. by 5'RACE. ING1 is localised to the
CC 13q33-34 chromosome region, to which a number of human cancers have
CC been mapped. ING1 nucleic acids can be used in the diagnosis of
CC breast cancer; a decreased level of ING1 mRNA indicates cancerous
CC cells. They can also be used in gene therapy methods to block the
CC proliferation of cancer cells.
XX
SQ Sequence 1902 BP; 574 A; 391 C; 461 G; 476 T; 0 other:

Query Match	70.7%	Score 605.6	DB 18	Length 1902
Best Local Similarity	95.6%	Pred. No. 3,8e-109		
Matches 623	Conservative 0	Mismatches 129	Indels 0	Gaps
QY 206	CTAGGCTGCTGGAGTGTGTGTCGGCGCGCGGATGAGATCCGGAAGAGAGCTAGACAG	265		
DB 1	CTGACCCGAGGGTGGGGCGCGCGCTGGCCCTGTGAAACAGATCTGGAAGAGAGCTGACGAG	60		
QY 266	TGTCACGAGCGCTTCAGTCCGGAGACAGACAGGGGCGCAGAAAGCGGGATCTGCTACTGT	325		
DB 61	TGTCACGAGCGCTTCAGTCCGGAGACAGACAGGGGCGCAGAAAGCGGGATCTGCTACTGT	120		
QY 326	GTGCAGCGCGCGCTGATCCGACAGCAGAGAGCTGGGGCGACGAGAAAGATCCAGATCGTAGC	385		
DB 121	GTGCAGCGCGCGCTGATCCGACAGCAGAGAGCTGGGGCGACGAGAAAGATCCAGATCGTAGC	180		
QY 386	CAGATGCTGGAGCTTGGTGGAGAACCCGACAGCGGCGAGGTGGACACAGCTGGAGCTGTTC	445		
DB 181	CAGATGCTGGAGCTTGGTGGAGAACCCGACAGCGGCGAGGTGGACACAGCTGGAGCTGTTC	240		
QY 446	GAGCGCGCAGCAGAGCTGGGGGAGACACAGCGGCGCAACAGCGGCGAGCGGACAGG	505		
DB 241	GAGCGCGCAGCAGAGCTGGGGGAGACACAGCGGCGCAACAGCGGCGAGCGGACAGG	300		
QY 506	CCCAAAAGCGAGGCGGCGCAGCGCTGACAAAGCCCAACAGCAAGCGCTCACGGCGGCGAG	565		
DB 301	CCCAATGGCGATGGCGGTAGCGCAGTCTGACAAGCCCAACAGCAAGCGCTCACGGCGGCGAG	360		
QY 566	CGCACAACGAGAACCGTGGAGAACGCGTCCAGCAACCAACGAGACAGAGCGGCGCTCG	625		
DB 361	CGCACAACGAGAACCGTGGAGAACGCGTCCAGCAACCAACGAGACAGAGCGGCGCTCG	420		
QY 626	GGCACAACCCAAAGAGAAAGAGCCCAAGCTCCAAAGAAAGAAAGAGCGCTCCAAAGCCCAAG	685		

Db	421	GGGACACCCAAAGGAGAGAAAGGCCAAGACCTCCAAAGAAAGAGGCTCCAAAGGCCAAG	480
QY	686	GGGAGACGAGAGGCGTCCTCCGCGACACTCCCATGAGACCCCAACCAACCCAGTACTGT	745
Db	481	GGCGAGCAGAGAGCGCTCCCTGCGGACCTCCCATGAGACCCCAAGAACCCAGTACTGT	540
QY	746	CTGTGCAACCAAGTCTCTATGTGGGAGATGATGCTGCGACACGACGATGCCCATTC	805
Db	541	CTGTGCAACCAAGTCTCTATGTGGGAGATGATGCTGCGACACGACGATGCCCATTC	600
QY	806	GAGTGGTCCACTCTCTGTCGGTGGGGGCTCAATCAATAACCCCAAGGGCAAGT	857
Db	601	GAGTGGTCCACTCTCTGTCGGTGGGGCTCAATCAATAACCCCAAGGGCAAGT	652

RESULT 10
AAV62285
ID AAV62285 standard; cDNA; 1902 BP.
XX
AC AAV62285;
XX

DT 18-JAN-1999 (first entry)
XX
XX Partial INGI partial cDNA sequence.
DE
XX
XX INGI gene; p33ING1; human; apoptosis; cell death; breast cancer;
KW brain tumour; gene therapy; tumour suppressor; ss.
XX
XX Homo sapiens.
XX

	Location/Qualifiers 109.741 /*tag- a
FH	Key
FT	CDS
FT	
XX	
XX	
PN	W09844102-A2.
XX	
PD	08-OCT-1998.
XX	
DE	26-MAR-1998.
	08W0-CA00277

XX 20 MAR-1997; 97US-0828158.
XX
PR 27-MAR-1997; 97US-0828158.
XX
XX
PA (UYTE-) UNIV TECHNOLOGIES INT INC.
XX
PI Garkavtsev I, Helpling CC, Johnston RW, Radowol K;
XX WPI, 1998-542700/46.
XX
DR P-PSDB; AAW79674.
XX

PT Modulating eukaryotic apoptosis by increasing p33ING1 activity -
PT using p33ING1 derivatives, to induce apoptosis in cancer cells, and
PT in the investigation of apoptotic pathways
XX
PS Example 2; Fig 2; 66pp; English.
XX

CC This is the nucleotide sequence of a human INGI1 (Inhibitor of
CC Growth) partial cDNA clone that codes for a p133ING1 polypeptide
CC (see AAW79674), a novel inhibitor of cell growth and a candidate
CC tumour suppressor. INGI1 is a new gene that is expressed in normal
CC mammary epithelial cells, but which is expressed only at lower
CC levels in several cancerous mammary epithelial cell lines and is
CC not expressed in many primary brain tumours. To isolate INGI1, a
CC subtractive hybridisation of breast cancer cell line cDNAs was
CC performed with cDNA from normal mammary epithelial cells, and
CC subtracted cDNAs were cloned into retrovirus vector pLINCX.
CC Following passage through a packaging line, normal mouse mammary
CC epithelial cells were infected, and infected cells were injected
CC into nude mice. Putative transforming fragments from tumours were
CC isolated by PCR (see AAW62290-91) and subcloned into LINCX. An INGI1
CC fragment was obtained and used to screen normal human fibroblast
CC and HeLa cell cDNA libraries. 2 Clones were sequenced to obtain
CC the partial INGI1 sequence. The complete cDNA sequence (see